This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Chronos/Shire CNS Program

Chronos Therapeutics, Ltd.

Description: Chronos Therapeutics has acquired three preclinical development programs targeting Central Nervous System (CNS) diseases from a subsidiary of Shire.

Deal Structure: Chronos and Shire
In July 2016, Chronos Therapeutics announced the acquisition of three preclinical development programs targeting Central Nervous System (CNS) diseases from a subsidiary of Shire. Chronos has acquired all intellectual property, know-how, development and marketing rights for each program on a worldwide basis. Shire becomes a strategic equity investor in Chronos and is eligible for milestone payments on regulatory approval of products relating to the programs, followed by royalties and milestone payments on sales of the products. Shire has a right of first negotiation for each of the programs on commercial terms, as well as rights to re-acquire each of the programs in the event that Chronos does not invest specified minimum amounts.

Partners: Shire Pharmaceuticals Group PLC


Chronos/Shire CNS Program News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug